发明名称 HUMANIZED ANTIBODIES
摘要 Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
申请公布号 US2017073395(A1) 申请公布日期 2017.03.16
申请号 US201615155324 申请日期 2016.05.16
申请人 Pfizer Inc. 发明人 Finlay William James Jonathan;Tchistiakova Lioudmila;Bennett Eric M.
分类号 C07K16/00;C07K16/40;C07K16/18 主分类号 C07K16/00
代理机构 代理人
主权项 1. A humanized antibody or antigen-binding fragment thereof that binds to a target antigen, wherein: (a) said antibody or antigen-binding fragment thereof comprises (i) a VH domain comprising: a human germline VH framework sequence, and CDR-H1, CDR-H2, and CDR-H3; and (ii) a VL domain comprising: a human germline VL framework sequence, and CDR-L1, CDR-L2, and CDR-L3; (b) said CDR-L1, CDR-L2, CDR-L3, CDR-H1, and CDR-H2 are derived from corresponding CDRs from a non-human donor antibody that binds to said target antigen; (c) for each position within said CDR-L1, CDR-L2, CDR-L3, CDR-H1, and CDR-H2, the residue is either human germline residue from said human germline VL or VH, or corresponding residue from said non-human donor antibody; (d) said CDR-L1, CDR-L2, CDR-L3, CDR-H1, and CDR-H2 each comprises at least one more human germline residue as compared to the corresponding non-human donor CDR, (e) said CDR-L1, CDR-L2, CDR-L3, CDR-H1, and CDR-H2 each comprises at least one more non-human donor residue as compared to the corresponding human germline VH or VL CDR; and (f) for each position within CDR-H3, the residue is any one of the 20 natural amino acid residues.
地址 New York NY US